Encoded Therapeutics raised $275 million in a Series F to push ETX101 into the next clinical phase for Dravet syndrome. The company’s lead program targets SCN1A-positive patients, with interim Phase I/II data previously presented at the European Epilepsy Congress showing substantial and sustained seizure frequency reductions alongside developmental improvements. The financing also supports manufacturing scale-up through internal vertical integration rather than reliance on contract capacity. Encoded is enrolling children in a registration-directed trial and is expanding into adolescents up to age 18. The round further positions ETX301—an additional gene therapy for post-amputation neuroma pain—for an IND filing expected in 2027, signaling Encoded’s intent to build a multi-indication neuroscience portfolio on a unified genetic-therapy platform.